Tag: amyloidosis research consortium
August 24, 2018
ARC CEO Named 2018 Rare Champion of Hope
Earlier this month, ARC CEO, Isabelle Lousada was among a small group of honorees named 2018 RARE Champion of Hope award recipients by Global Genes. (more…)
Read More
August 10, 2018
FDA approves first treatment for hereditary ATTR amyloidosis
The U.S. Food and Drug Administration today approved Patisiran, a novel therapy for the treatment of hereditary ATTR amyloidosis polyneuropathy. (more…)
Read More
July 26, 2018
New hATTR Treatments Under Review for their ‘Value for Money’
Two vitally important reviews are underway for patisiran and inotersen, new treatments that have been trialed for hATTR patients. One review is led by the National Institute for Health and Clinical Excellence (NICE) in the UK. (more…)
Read More
July 13, 2018
ARC CEO Named Representative of Patient Engagement Collaborative
To strengthen patient involvement, the U.S. Food and Drug Administration (FDA) and the Clinical Trials Transformation Initiative (CTTI) announced the launch of the Patient Engagement Collaborative (PEC). (more…)
Read More
April 20, 2018
ARC Provides Vital Feedback for Evaluation of New hATTR Treatments
The Institute of Clinical and Economic Review (ICER), is an independent organization that seeks to improve healthcare value by providing comprehensive clinical and cost-effectiveness analyses of treatments. (more…)
Read More
- Categories
- Archives
- August 2018 (2)
- July 2018 (2)
- April 2018 (3)
- March 2018 (2)
- February 2018 (3)
- January 2018 (2)
- December 2017 (4)
- November 2017 (2)
- October 2017 (1)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- April 2017 (1)
- February 2017 (1)
- December 2016 (2)
- October 2016 (2)
- September 2016 (1)
- July 2016 (4)
- June 2016 (4)
- May 2016 (1)
- April 2016 (2)
- March 2016 (1)
- February 2016 (2)
- December 2015 (1)
- November 2015 (3)
- October 2015 (1)
- September 2015 (1) More
